News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Lonza enters a partnership with Vineti to advance its ‘vein-to-vein’ delivery network, creating an end-to-end ordering and manufacturing process in support of cell and gene therapy development.
Lonza extends its deal with Omeros for the commercial manufacture of a treatment for thrombotic microangiopathy, ahead of filing with the US FDA and the EMA.
Citing evidence from two completed clinical trials, the WHO recommends dolutegravir as the preferred treatment for all patients with HIV.